Extract

A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) . Th e primary purpose of the trial is to evaluate the long-term effectiveness of repeated courses ( a maximum of 9 treatment courses) of ofatumumab in RA patients who previously received ofatumumab or placebo in Trial Hx-CD20-403.

Inclusion criteria

• Arthritis (rheumatoid)

Country

• Denmark
• Hungary
• Poland
• United Kingdom
• United States

Links

• ictrp
• gsk
• nct